Abstract
Chlorpromazine (CPZ), a major tranquilizer, was found to be a potent inhibitor of lecithin:cholesterol acyltransferase (LCAT, EC 2.3.1.43) in the plasma of normal man, rat, rabbit and dog in vitro. The inhibitory effect of CPZ reached 35–50% at 0.5 mM depending on species; dog plasma LCAT appeared to be somewhat more sensitive than that of the other species. In rats fed CPZ or lidocaine for 14 days (0.05% in the diet), there was no statistically significant change in total plasma cholesterol levels or the size of the plasma-free (unesterified) cholesterol pool. However, 5 hr after an intracardial injection of [14C] cholesterol, the percentage of plasma [14C] cholesterol that was esterified was significantly lower (ca. 6%, p<0.05) in the CPZ-treated group, suggesting that CPZ may also inhibit LCAT to some extent in vivo. The percentage of plasma [14C] cholesterol esterified in the lidocainetreated group was similar to control values and did not reflect its ability to inhibit LCAT in vitro.
Similar content being viewed by others
References
Sugano, M., and Portman, O.W. (1965) Arch. Biochem. Biophys. 109, 302–315.
Glosmet, J.A., Janssen, E.T., Kennedy, R., and Dobbins, J. (1966) J. Lipid Res. 7, 638–648.
Fielding, C.J., and Fielding, P.E. (1971) FEBS Lett. 15, 355–358.
Bell, F.P., and Hubert, E.V. (1980) Lipids 15, 811–814.
Piran, U., and Nishida, T. (1976) J. Biochem. 80, 887–889.
Aron, L., Jones, S., and Fielding, C.J. (1978) J. Biol. Chem. 253, 7220–7226.
Piran, U., and Nishida, T. (1979) Lipids 14, 478–482.
Seeman, P. (1972) Pharmacol. Rev. 24, 583–655.
Bickel, M.H. (1975) J. Pharm. Pharmac. 27, 733–738.
Rehnborg, C.S., and Nichols, A.V. (1964) Biochim. Biophys. Acta 84, 596–603.
Nichols, A.V., and Smith, L. (1965) J. Lipid Res. 6, 206–210.
Glosmet, J.A., Norum, K.R., Nichols, A.V., Forte, T., King, W.C., Albers, J.J., Mitchell, C.D., Applegate, K.R., and Gjone, E. (1974) Scand. J. Clin. Lab. Invest. (Suppl. 137) 33, 165–171.
Bell, F.P., and Schwartz, C.J. (1971) Biochim. Biophys. Acta 231, 553–557.
Stokke, K.T., and Norum, K.R. (1971) Scand. J. Clin. Lab. Invest. 27, 21–27.
Lacko, A.G., Rutenberg, H.L., and Soloff, L.A. (1973) Biochem. Med. 7, 178–183.
Bell, F.P. (1976) Exp. Mol. Pathol. 25, 279–292.
Bell, F.P., Lofland, H.B., and Stokes, N.A. (1970) Atherosclerosis 11, 235–246.
Block, W.D., Jarrett, K.J., and Lewis, J.B. (1966) Clin. Chem. 12, 681–689.
Sperry, W.M., and Webb, M. (1950) J. Biol. Chem. 187, 97–106.
Papahadjopoulos, D., Jacobson, K., Poste, G., and Shepherd, G. (1975) Biochim. Biophys. Acta 394, 504–519.
Scherphof, G., and Westernberg, G. (1975) Biochim. Biophys. Acta 398, 442–451.
Bowley, M., Cooling, J., Burditt, S.L., and Brindley, D.N. (1977) Biochem. J. 165, 447–454.
Neal, M.J., Butler, K.W., Polnaszek, C.F., and Smith, I.C.P. (1976) Molec. Pharmacol. 12, 144–155.
Lee, A.G. (1977) Molec. Pharmacol. 13, 474–487.
Jain, M.K., Eskow, K., Kuchibhotla, J., and Colman, R.W. (1978) Thromb. Res. 13, 1067–1075.
Keefe, E.B., Blankenship, N.M., and Scharschmidt, B.F. (1980) Gastroenterology 79, 222–231.
Yokoyama, S., Fukushima, D., Kupferberg, J.P., Kezdy, F.J., and Kaiser, E.T. (1980) J. Biol. Chem. 255, 7333–7339.
Glosmet, J.A. (1979) Prog. Biochem. Pharmacol. 15, 41–66.
Clark, M.L., Ray, T.S., Paredes, A., Ragland, R.E., Costiloe, J.P., Smith, C.W., and Wolf, S. (1967) Psychosomat. Med. 29, 634–642.
Clark, M., Dubowski, K., and Colmore, J. (1970) Clin. Pharmacol. Therapeut. 11, 883–889.
Boyes, R.N., Scott, D.B., Jebson, P.J., Godman, J.J., and Julian, D.J. (1971) Clin. Pharmacol. Ther. 12, 105–116.
Rowland, M., Thompson, P.D., Guichard, A., and Melmon, K.L. (1971) Ann. N.Y. Acad. Sci. 179, 383–398.
Efron, D.H., Harris, S.R., Manian, A.A., and Gaudette, L.E. (1971) Psychopharmacologia 19, 207–223.
VanLoon, E.J., Flanagan, T.L., Novick, W.J., and Maass, A.R. (1964) J. Pharm. Sci. 53, 1211–1213.
Author information
Authors and Affiliations
About this article
Cite this article
Bell, F.P., Hubert, E.V. Inhibition of LCAT in plasma from man and experimental animals by chlorpromazine. Lipids 16, 815–819 (1981). https://doi.org/10.1007/BF02535035
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02535035